Peter Marks

9.6k total citations · 2 hit papers
103 papers, 5.0k citations indexed

About

Peter Marks is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Peter Marks has authored 103 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 27 papers in Hematology and 18 papers in Genetics. Recurrent topics in Peter Marks's work include Hemoglobinopathies and Related Disorders (11 papers), Venous Thromboembolism Diagnosis and Management (10 papers) and SARS-CoV-2 and COVID-19 Research (8 papers). Peter Marks is often cited by papers focused on Hemoglobinopathies and Related Disorders (11 papers), Venous Thromboembolism Diagnosis and Management (10 papers) and SARS-CoV-2 and COVID-19 Research (8 papers). Peter Marks collaborates with scholars based in United States, United Kingdom and Canada. Peter Marks's co-authors include Robert M. Califf, Frederick R. Maxfield, Steven A. Anderson, Janet Woodcock, Thomas P. Gross, Robert Temple, Rachel E. Sherman, Melissa A. Robb, Lisa M. LaVange and Jeffrey Shuren and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Peter Marks

96 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Real-World Evidence — What Is It and What Can It Tell Us?

2016 1.3k citations Steven A. Anderson, Peter Marks et al. New England Journal of Medicine profile →
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

2024 150 citations Nicole Verdun, Peter Marks New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Marks United States	29	1.5k	783	635	555	516	103	5.0k
Jeffrey A. Kant United States	32	1.5k 1.0×	848 1.1×	782 1.2×	475 0.9×	250 0.5×	82	4.5k
Wouter W. van Solinge Netherlands	39	2.5k 1.6×	541 0.7×	1.1k 1.7×	555 1.0×	919 1.8×	192	6.3k
David‐Alexandre Trégouët France	45	1.9k 1.2×	948 1.2×	564 0.9×	646 1.2×	1.3k 2.5×	189	6.8k
Eric R. Siegel United States	41	2.3k 1.5×	1.7k 2.2×	315 0.5×	423 0.8×	1.1k 2.2×	260	6.3k
Yi–Ju Chen Taiwan	49	1.9k 1.2×	974 1.2×	539 0.8×	1.2k 2.2×	132 0.3×	246	7.8k
Sylvia Heeneman Netherlands	45	1.6k 1.1×	567 0.7×	418 0.7×	1.3k 2.4×	512 1.0×	155	6.8k
Ming‐Lung Yu Taiwan	53	1.1k 0.7×	544 0.7×	217 0.3×	502 0.9×	187 0.4×	490	10.8k
Johanna M. Seddon United States	67	4.5k 2.9×	1.2k 1.6×	329 0.5×	1.7k 3.0×	340 0.7×	192	15.8k
S. A. Roberts United Kingdom	47	1.6k 1.0×	933 1.2×	307 0.5×	388 0.7×	158 0.3×	165	6.5k
Rachel I. Vogel United States	40	1.5k 1.0×	1.5k 1.9×	563 0.9×	459 0.8×	105 0.2×	234	5.4k

Countries citing papers authored by Peter Marks

Since Specialization

Citations

This map shows the geographic impact of Peter Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Marks more than expected).

Fields of papers citing papers by Peter Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Marks. The network helps show where Peter Marks may publish in the future.

Co-authorship network of co-authors of Peter Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Marks. A scholar is included among the top collaborators of Peter Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Marks. Peter Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marks, Peter. (2025). Restoring Confidence in Public Health. New England Journal of Medicine. 393(21). 2075–2077.

Fowler, Tom, Andrew Dodgson, Jeanette Hall, et al.. (2025). Key SARS-CoV-2 testing strategies implemented in the UK: rationale and impact. Journal of the Royal Society of Medicine. 118(4). 112–120.

Buccheri, Renata, Barbee Whitaker, Lance M. Pollack, et al.. (2025). Performance of a whole blood immunoassay for tenofovir detection and correlation with self‐reported pre‐exposure prophylaxis use in HIV‐negative men who have sex with men interested in blood donation. Transfusion. 65(7). 1273–1283. 1 indexed citations

Marks, Peter & Robert M. Califf. (2024). Is Vaccination Approaching a Dangerous Tipping Point?. JAMA. 331(4). 283–283. 16 indexed citations

Verdun, Nicole & Peter Marks. (2024). Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine. 390(7). 584–586. 150 indexed citations breakdown →

Custer, Brian, Barbee Whitaker, Lance M. Pollack, et al.. (2023). HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study. Transfusion. 63(10). 1872–1884. 6 indexed citations

Evans, William J., Roger A. Fielding, Venkatesh Krishnan, et al.. (2023). Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development. The Journals of Gerontology Series A. 78(Supplement_1). 94–100.

Eyre, David W., Matthias E. Futschik, Jia Wei, et al.. (2023). Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study. The Lancet Infectious Diseases. 23(8). 922–932. 32 indexed citations

Brooks, John T., Peter Marks, Robert H. Goldstein, & Rochelle P. Walensky. (2022). Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health. New England Journal of Medicine. 387(13). 1151–1153. 34 indexed citations

10.

Cannon, Paula M., Aravind Asokan, Agnieszka Czechowicz, et al.. (2021). Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Human Gene Therapy. 32(1-2). 31–42. 17 indexed citations

11.

Abou‐El‐Enein, Mohamed, Magdi Elsallab, Steven A. Feldman, et al.. (2021). Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discovery. 2(5). 408–422. 182 indexed citations

12.

Shah, Anand, Peter Marks, & Stephen M. Hahn. (2020). Unwavering Regulatory Safeguards for COVID-19 Vaccines. JAMA. 324(10). 931–931. 45 indexed citations

13.

Marks, Peter, Jay S. Epstein, & Luciana Borio. (2016). Maintaining a Safe Blood Supply in an Era of Emerging Pathogens. The Journal of Infectious Diseases. 213(11). 1676–1677. 15 indexed citations

14.

Kirschbaum, Mark, Ivana Gojo, Stuart L. Goldberg, et al.. (2014). A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167(2). 185–193. 96 indexed citations

15.

Marks, Peter. (2009). Coagulation Disorders in the ICU. Clinics in Chest Medicine. 30(1). 123–129. 8 indexed citations

16.

Marks, Peter. (2007). Management of Thromboembolism in Pregnancy. Seminars in Perinatology. 31(4). 227–231. 4 indexed citations

17.

Glogauer, Michael, Christophe C. Marchal, Fei Zhu, et al.. (2003). Rac1 Deletion in Mouse Neutrophils Has Selective Effects on Neutrophil Functions. The Journal of Immunology. 170(11). 5652–5657. 255 indexed citations

18.

Onda, Hiroaki, et al.. (1999). Tsc2+/– mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. Journal of Clinical Investigation. 104(6). 687–695. 309 indexed citations

19.

Wriggers, Willy, et al.. (1998). Cofilin and gelsolin segment-1: molecular dynamics simulation and biochemical analysis predict a similar actin binding mode. Journal of Molecular Biology. 282(5). 921–932. 58 indexed citations

20.

Marks, Peter & Peter Emerson. (1974). Increased Incidence of Deep Vein Thrombosis after Myocardial Infarction in Non-smokers. BMJ. 3(5925). 232–234. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact